Intertryp research and innovation activities are aimed at controlling and durably eliminating human and animal diseases caused by trypanosomatids. These activities are based on research and development in close proximity with populations, and on upstream research in molecular or cellular biology.

Our research focuses on the improvement of monitoring tools adapted to the context of elimination (including diagnostic tests in a context of low prevalences), the development and evaluation of new therapeutic molecules, vector control, and involvement in vaccine research. Intertryp has a strong expertise in the field as it is at the origin of the development of the first vaccine against a disease caused by a trypanosomatid, the canine leishmaniasis.

In the longer term, the study of co-evolution mechanisms between parasites, vectors and symbionts, and mammalian hosts (animal and human) is favored, taking into account a changing environment (adaptation to high human densities, landscape transformation, biodiversity). This co-evolution also involves understanding the mechanisms of tolerance to infection and disease in humans and animals, for which Intertryp is a recognized pioneer and the only one in the world to conduct this type of research, particularly regarding longitudinal cohort studies.